Among the analytes, fibroblast growth factor-23 (FGF-23) was found to be significantly elevated in PAH patients and showed strong associations with disease severity, adverse hemodynamics, and higher risk stratification profiles. This evidence concerns the gene FGF23 and pulmonary arterial hypertension.